Investment Rating - The report maintains an "Increase" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of 0.22% this week, ranking 13th out of 31 sectors, and a year-to-date decline of 0.13%, ranking 23rd out of 31 sectors [8]. - A significant milestone was achieved with the approval of the first invasive brain-computer interface medical device by the National Medical Products Administration, marking a transition from technical exploration to clinical application, which opens commercial opportunities in the field of neuroregulation and implantable medical devices [9]. - The launch of a national major scientific research project for innovative drugs targeting Alzheimer's disease indicates the government's commitment to addressing urgent clinical needs in the central nervous system, potentially accelerating technological breakthroughs and industrialization in this area [10]. Company Dynamics - Kanglong Chemical announced a strategic partnership with Eli Lilly for the commercialization of the oral GLP-1 drug Orforglipron, receiving a $200 million investment to enhance its technical capabilities [11]. - Laika Pharmaceuticals successfully completed Phase I SAD studies for LAE102 in the U.S. and is planning Phase II trials, indicating progress in global development [12]. - Hotgen Biotech's innovative drug SGC001 has completed its first administration in Phase II clinical trials for treating acute myocardial infarction, marking a significant advancement in this therapeutic area [13]. - East China Pharmaceutical's self-developed dual-target ADC drug HDM2024 has received FDA approval for Phase I clinical trials in the U.S., enhancing its competitiveness in the oncology field [14]. - Kelun Biotech's SKB575 has been approved for clinical trials targeting atopic dermatitis, showcasing its potential as a best-in-class treatment with a long dosing interval [15]. Suggested Focus Areas - The report suggests focusing on the innovative drug supply chain and the brain-computer interface sector for potential investment opportunities [16].